59.4%United States United States
8.7%United Kingdom United Kingdom
5%Canada Canada
4%Australia Australia
3.5%Philippines Philippines
2.6%Netherlands Netherlands
2.4%India India
1.6%Germany Germany
1%France France
0.7%Poland Poland

Today: 210
Yesterday: 251
This Week: 210
Last Week: 2221
This Month: 4798
Last Month: 6796
Total: 129397

Summary

User Rating: / 0
PoorBest 
Reports - Models of Good Practice in Drug Treatment

Drug Abuse

1 Summary

Objective of the project “Models of good practice in drug treatment in Europe
(‘Moretreat’)” was to deliver guidelines or treatment improvement protocols for key
interventions in drug treatment.
This “Moretreat”-project aimed to identify and evaluate models of good practice in drug
treatment in Europe. European drug treatment interventions were identified and
collected from all European Union Member States. The guidelines are based on the
inventory of international and European evidence. Regional European evidence that is
not available in English and not represented in international scientific journals has been
collected in addition. Based on a consensus process good practice guidelines have been
formulated for main treatment interventions as well as for the system level of drug
treatment services.
The overall aim of the project was to contribute to guidance in order to improve drug
treatment and health care in the EU-Member States. Therefore the report presents
recommendations for the improvement of drug treatment in Europe which are to support
health authorities, commissioners, providers and professionals.
The following results of the project are presented in this report:
• Reviews of good practice and evidence for different drug treatment intervention
modalities and their effectiveness for different target populations.
• Good practice guidelines for the improvement of drug treatment interventions in
Europe (short and comprehensive versions with an unified structure).
• A proposal for the development of platforms for treatment guidance on a European
level that provides a basis for the continued improvement of drug treatment in the
Member States (sustainability).